Abstract:When a v i r h and a living cell are brought close together, there is no discernible reaction between them in the great majority of instances. However, if the virus and the host cell possess those complementary properties which permit designation of the virus as infectious and the host cell as susceptible, then a series of reactions may occur which leads to an increase in the amount of virus. The reactions which follow infection of a susceptible host cell with a virus have many aspects (Woodruff and Goodpasture, 1930). One of these is the stepwise process which results in the development of new viral particles (Burnet, 1929; Ellis and Delbriick, 1939; Delbriick, 1940a and 1910b; Henle, et al. 1947; Ginsberg and Horsfall, 1949a and 1951a). This process is termed viral multiplication or proliferation and is affected in various ways by a large number of factors (Horsfall, 1949). Some of the more prominent factors are: (1) the genetic features of the host cell and the virus; (2) the metabolic state of the host cell; (3) the presence of another virus; and (4) the composition of the extracellular environment. The most evident ways in which such factors act are the augmentation or inhibition of viral proliferation so that either more or less virus develops (Horsfall, 195 1). Before proceeding to a more detailed consideration of factors which, a t the cellular level, have an effect upon the multiplication of viruses, another aspect of animal virus infections deserces emphasis. Viruses which induce infections in animal species do not usually come into contact with host cells susceptible to infection immediately after gaining en& to the body. In most instances, the infectious agent is transported from the portal of entry to the tissue that contains suceptible cells. In no case is it known that all types of cells are equally susceptible to infection. In many instances, susceptibility is restricted to cells of a single type; in some, to cells present only in a single tissue. During the period of transport to susceptible cells, the naked viral particle is in a highly vulnerable condition and can be prevented readily from reaching cells it can infect. The most specific and probably the most effective substances which can act at this stage are antibodies directed against the agent. Specific antiviral antibodies develop as a result of contact with the agent. Usually, though not always, they are a reflection of immunity and are found not only in the blood, but also in the tissue fluids, as well as in the secretions of the mucous membranes (Francis, et al. 1943). Much evidence indicates that the interaction between antibody and viral particle prevents adsorption of the virus by susceptible cells and thus the process of multiplication does not begin (Delbriick, 1945a; Volkert and Horsfall, 1947). In contrast to the striking effectiveness of antibodies in preventing infection of the cell is their marked lack of effect upon viral proliferation once the virus has pene-

Decree No. 18717-PLAN-S, 14 December 1988.

Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1

Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes

[On a rare case of bicornuate uterus with double cervix, double vagina, hematocolpos, hematometra, right unilateral hematosalpinx, partial atresia of the vagina and right renal aplasia].

[Current Indications for Surgery in Small Cell Lung Cancer].

Production of composite neutral Higgs bosons in photoproduction and e+e- experiments.

Splenic irradiation portals.

Metformin protects the myocardium against isoproterenol-induced injury in rats through alleviating endoplasmic reticulum stress.

[Chronic intestinal pseudo-obstruction as a paraneoplastic presentation of limited-stage small cell lung cancer].

FACTORS CONCERNED WITH VIRAL PROLIFERATION IN VIVO

Metformin protects against pericyte apoptosis and promotes neurogenesis through suppressing JNK p38 MAPK signalling activation in ischemia/reperfusion injury

Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury

Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages

Metformin relieves H/R-induced cardiomyocyte injury through miR-19a/ACSL axis - possible therapeutic target for myocardial I/R injury

Acute Administration of Metformin Protects Against Neuronal Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury via Regulation of the AMPK/CREB/BDNF Pathway

Metformin Alleviates Sepsis-associated Myocardial Injury by Enhancing AMPK/mTOR Signaling Pathway-mediated Autophagy

Metformin alleviates cerebral ischemia/reperfusion injury aggravated by hyperglycemia via regulating AMPK/ULK1/PINK1/Parkin pathway-mediated mitophagy and apoptosis

AMPK/mTOR-mediated therapeutic effect of metformin on myocardial ischaemia reperfusion injury in diabetic rat

Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury

High-glucose-induced apoptosis, ROS production and pro-inflammatory response in cardiomyocytes is attenuated by metformin treatment via PP2A activation

Metformin ameliorates ferroptosis in cardiac ischemia and reperfusion by reducing NOX4 expression via promoting AMPKα